• Earlier this week, Scholar Rock announced it had removed Catalent Indiana from all commercial fill-finish roles in apitegromab’s U.S. BLA for spinal muscular atrophy, withdrawn and planned to resubmit its European filing with an alternate facility, and secured PMDA alignment to file a Japanese application without new local trials.
• This set of regulatory and manufacturing moves materially reduces operational risk around apitegromab’s global rollout by shifting to a compliant U.S. facility with existing commercial experience and clarifying the path to filings across the U.S., Europe and Japan.
• We’ll now examine how the PMDA’s agreement to allow a Japanese filing without local trials could reshape Scholar Rock’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Scholar Rock Holding Investment Narrative Recap

To own Scholar Rock today, you have to believe apitegromab can move from an investigational asset to a global SMA treatment while the company absorbs heavy launch spending and ongoing losses. The latest manufacturing and regulatory updates ease a key near term operational risk around the PDUFA decision on September 30, 2026, but the biggest business risk remains whether real world use ultimately supports the ambitious expectations already embedded in the share price.

Among the latest announcements, the PMDA’s decision to allow a Japanese filing without local clinical trials stands out, because it clarifies a path to a third major market using the existing global data package. For investors watching near term catalysts, this aligns Japan with the U.S. BLA review and the planned European resubmission, concentrating attention on how regulators across these regions interpret the same apitegromab evidence set.

Yet against this clearer regulatory path, investors should be aware that...

Scholar Rock Holding's narrative projects $402.0 million revenue and $76.0 million earnings by 2029. This implies an earnings increase of about $485 million from -$408.7 million today.

Uncover how Scholar Rock Holding's forecasts yield a $59.31 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Scholar Rock between US$59.31 and US$190.32 per share, underscoring how far views can stretch. Set against that wide range, the company’s dependence on apitegromab’s regulatory progress is a reminder that outcomes around a single drug can have outsized effects, so it is worth weighing several contrasting scenarios before forming a view.

Explore 3 other fair value estimates on Scholar Rock Holding - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Scholar Rock Holding research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Scholar Rock Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Scholar Rock Holding's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.